Juvenile myelomonocytic leukemia natural history: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{Juvenile myelomonocytic leukemia}} {{CMG}} ==Overview== ==References== {{reflist|2}} {{Hematological malignancy histology}} {{SIB}} Category:Hematology [[Category:Ty...")
 
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Juvenile myelomonocytic leukemia}}
{{Juvenile myelomonocytic leukemia}}
{{CMG}}
{{CMG}}
==Prognosis==
Prognosis refers to how well a patient is expected to respond to treatment based on their individual characteristics at time of diagnosis. In JMML, three characteristic areas have been identified as significant in the prognosis of patients:


==Overview==
{| class="wikitable"
|-
! Characteristic
! Values indicating a more favorable prognosis
|-
| Sex
| Male
|-
| Age at diagnosis
| < 2 years old
|-
| Other existing conditions
| Diagnosis of [[Noonan syndrome]]
|}
 
Without treatment, the survival of children with JMML is approximately 5%.  Only Hematopoietic Stem Cell Transplantation (HSCT), commonly referred to as a bone marrow or (umbilical) cord blood transplant, has been shown to be successful in curing a child of JMML.  With HSCT, recent research studies have found the survival rate to be approximately 50%.  Relapse is a significant risk after HSCT for children with JMML.  It is the greatest cause of death in JMML children who have had stem cell transplants. Relapse rate has been recorded as high as 50%. Many children have been brought into remission after a second stem cell transplant.
 
==Relapse==
After bone marrow transplant, the relapse rate for children with JMML may be as high as 50%.  Relapse often occurs within a few months after transplant and the risk of relapse drops considerably at the one-year point after transplant.  A significant number of JMML patients do achieve complete remission and long-term cure after a second bone marrow transplant, so this additional therapy should always be considered for children who relapse.


==References==
==References==
Line 8: Line 28:


{{Hematological malignancy histology}}
{{Hematological malignancy histology}}
{{SIB}}
 


[[Category:Hematology]]
[[Category:Hematology]]

Latest revision as of 16:39, 9 August 2012

Juvenile myelomonocytic leukemia Microchapters

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Epidemiology & Demographics

Risk Factors

Screening

Causes of Juvenile myelomonocytic leukemia

Differentiating Juvenile myelomonocytic leukemia from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

MRI

CT

Echocardiography or Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgical Therapy

Radiation Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Juvenile myelomonocytic leukemia natural history On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Juvenile myelomonocytic leukemia natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Juvenile myelomonocytic leukemia natural history

CDC on Juvenile myelomonocytic leukemia natural history

Juvenile myelomonocytic leukemia natural history in the news

Blogs on Juvenile myelomonocytic leukemia natural history

to Hospitals Treating Juvenile myelomonocytic leukemia

Risk calculators and risk factors for Juvenile myelomonocytic leukemia natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Prognosis

Prognosis refers to how well a patient is expected to respond to treatment based on their individual characteristics at time of diagnosis. In JMML, three characteristic areas have been identified as significant in the prognosis of patients:

Characteristic Values indicating a more favorable prognosis
Sex Male
Age at diagnosis < 2 years old
Other existing conditions Diagnosis of Noonan syndrome

Without treatment, the survival of children with JMML is approximately 5%. Only Hematopoietic Stem Cell Transplantation (HSCT), commonly referred to as a bone marrow or (umbilical) cord blood transplant, has been shown to be successful in curing a child of JMML. With HSCT, recent research studies have found the survival rate to be approximately 50%. Relapse is a significant risk after HSCT for children with JMML. It is the greatest cause of death in JMML children who have had stem cell transplants. Relapse rate has been recorded as high as 50%. Many children have been brought into remission after a second stem cell transplant.

Relapse

After bone marrow transplant, the relapse rate for children with JMML may be as high as 50%. Relapse often occurs within a few months after transplant and the risk of relapse drops considerably at the one-year point after transplant. A significant number of JMML patients do achieve complete remission and long-term cure after a second bone marrow transplant, so this additional therapy should always be considered for children who relapse.

References

fi:Juveniili myelomonosyyttileukemia


Template:WikiDoc Sources